Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA therapy and 3D mapping for AFib treatment.

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Johnson & Johnson announced the nipocalimab Biologics License Application received Priority Review designation from the U.S Food and Drug ...